We are live on ! Find out more
AURA icon

Aura Biosciences

75 hedge funds and large institutions have $300M invested in Aura Biosciences in 2024 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 20

0.77% more ownership

Funds ownership: 79.5%80.27% (+0.77%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

2% less capital invested

Capital invested by funds: $307M → $300M (-$6.64M)

4% less funds holding

Funds holding: 7875 (-3)

20% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 15

57% less call options, than puts

Call options by funds: $6K | Put options by funds: $14K

Holders
75
Holders Change
-3
Holders Change %
-3.85%
% of All Funds
1.08%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
34
Reduced
20
Closed
15
Calls
$6K
Puts
$14K
Net Calls
-$8K
Net Calls Change
-$8K
Name Holding Trade Value Shares
Change
Change in
Stake
MCMC
1
Matrix Capital Management Company
New Hampshire
$52.3M
EAM
2
Eventide Asset Management
Massachusetts
$43.9M
Adage Capital Partners
3
Adage Capital Partners
Massachusetts
$36.9M +$3.08M +420,000 +9%
MVM
4
Medicxi Ventures Management
Jersey
$23M
BlackRock
5
BlackRock
New York
$22.7M +$4.11M +560,521 +23%
Citadel Advisors
6
Citadel Advisors
Florida
$17.7M -$9.8M -1,337,607 -36%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.4M +$586K +80,000 +5%
Franklin Resources
8
Franklin Resources
California
$11M
NCM
9
Nantahala Capital Management
Connecticut
$9.6M -$380K -51,825 -4%
LFCM
10
Long Focus Capital Management
Puerto Rico
$7.99M +$4.11M +561,766 +113%
Goldman Sachs
11
Goldman Sachs
New York
$7.79M +$244K +33,278 +3%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$7.33M +$1.38M +188,258 +24%
RCM
13
Regency Capital Management
Hawaii
$5.78M -$147K -20,081 -3%
State Street
14
State Street
Massachusetts
$5.5M +$1.16M +158,158 +28%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$4.34M -$160K -21,900 -4%
DC
16
Decheng Capital
California
$3.9M
LCS
17
Levin Capital Strategies
New York
$2.48M +$1.58M +216,266 +194%
Northern Trust
18
Northern Trust
Illinois
$2.21M -$29.2K -3,991 -1%
Ensign Peak Advisors
19
Ensign Peak Advisors
Utah
$1.9M -$771K -105,316 -29%
Dimensional Fund Advisors
20
Dimensional Fund Advisors
Texas
$1.89M +$306K +41,711 +20%
Fidelity Investments
21
Fidelity Investments
Massachusetts
$1.74M -$470K -64,203 -22%
ACM
22
ADAR1 Capital Management
Texas
$1.54M +$1.49M +203,237 New
PIM
23
Platinum Investment Management
Australia
$1.23M -$130K -17,787 -10%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$1.08M +$356K +48,549 +51%
Charles Schwab
25
Charles Schwab
California
$1.02M +$209K +28,500 +27%

AURA Hedge Fund Activity: Q2 2024 in Review

75 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q2 2024, worth a combined $300M — down 2.2% from $307M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of AURA and 12 opened new positions — a net loss of 3 holders — while 20 trimmed existing stakes and 34 added.

The largest buyer was Long Focus Capital Management, adding an estimated $4.11M. The largest seller was Citadel Advisors, cutting an estimated $9.8M.

  • 75 institutional investors held Aura Biosciences (AURA) as of Q2 2024, down from 78 in Q1 2024.
  • Funds reported $300M of Aura Biosciences stock for Q2 2024, down 2.2% quarter-over-quarter.
  • 12 funds opened new Aura Biosciences positions in Q2 2024 and 15 closed out, a net change of -3 holders.
  • The largest Aura Biosciences buyer in Q2 2024 was Long Focus Capital Management, an estimated $4.11M added.
  • The largest Aura Biosciences seller in Q2 2024 was Citadel Advisors, an estimated $9.8M sold.

Based on aggregated 13F filings for Q2 2024.